Tumor growth is dependent both on endothelial and tumor cells. The aim of this study was to investigate dynamically whether changes in tumor vasculature implicate tumor tissue degeneration during antiangiogenic therapies. In order to quantify intra-tumor vascularization and necrosis, we have used ultrasound technology. This study has identified essential parameters needed to quantify specifically and sensitively the number of microvessels and the extent of necrosis in xenografted human carcinomas during natural tumor evolution, using contrast-enhanced high-frequency ultrasonography with (HFCDUS) or without (HFUS) color Doppler. We showed that quantification of intra-tumor microvessels between HFCDUS and immunohistochemistry is correlated using an anti-CD31 antibody. Furthermore, quantification of tumor necrosis with HFUS was confirmed by histological examination of hematoxylin-eosin-saffraninstained sections over the observation period. Subsequently, for the assessment of novel angiogenic inhibitors, HFCDUS and HFUS were used to elucidate the underlying dynamics linking vessel inhibition and tumor eradication. We describe a novel application for HFCDUS/HFUS that constitutes an effective, convenient, and non-invasive method for clinical assessment of angiogenic inhibitors. In conclusion, we showed that tumor cells abruptly became necrotic following an antivascular therapy, whereas untreated tumors were protected from degeneration by a significant blood supply.
Introduction
Angiogenesis is required for growth of tumors beyond a certain size and is implicated in the metastatic process. 1 In many types of tumors, positive correlations between tumor vasculature and tumor invasion have been demonstrated. 2 All tumor types are amenable to targeted therapy against the angiogenic process. 3 Antiangiogenic therapy is a major antitumor strategy as shown by the large number of clinical trials involving angiogenesis inhibitors. Recently, Bevacizumab (Avastin), a monoclonal antibody against vascular endothelial growth factor (VEGF), was approved by the FDA for the treatment of patients with colon or renal cancer. 4 There are no currently markers of the net activity of this new class of anticancer agents to help clinicians in the assessment of tumor response. An appropriate measure of vessel development inhibition is needed to evaluate the efficacy of antiangiogenic agents at an early stage during a trial. 5, 6 High-frequency color Doppler ultrasonography (HFCDUS) imaging provides non-invasive and functionally relevant images of angiogenesis. Unenhanced CDUS studies have already shown that increased angiogenesis reflects tumorigenesis in many malignancies, but the resolution of CDUS is too low to detect tumor microvasculature. 7, 8 The detection threshold of CDUS is approximately 100 mm in vessel diameter. 9, 10 However, a new clinical approach consists in using microbubble contrast agents, such as Levovist, to increase acoustic signal sensitivity reflecting microvascular perfusion. [11] [12] [13] In order to predict antiangiogenic effects over a treatment period, contrast-enhanced HFCDUS was used in this study.
Quantification of vessels on tissue sections by immunohistochemistry (IHC) is a widely used method in preclinical studies. Among preclinical quantification techniques, the determination of microvessel density (MVD) after IHC has been commonly used. MVD measures the number of vessels per mm 2 within a tissue sample and is accepted as a standard indicator of angiogenesis. 6 Histological quantification of vessels is a stand-alone measure that is unsuitable for monitoring antiangiogenic effects over a treatment period. In contrast, sonographic images are indicative of vasculature within the whole tumor volume (mm 3 ). After antiangiogenic therapy, capillary growth inhibition induces an inhibition of tumor growth by tissue degeneration through oxygen privation. Some collagenderived angiogenic inhibitors also act directly on tumor cells, inducing cell death through an apoptotic mechanism, as we previously demonstrated with Canstatin. 14 Therefore, it is important to monitor simultaneously changes in angiogenesis and tumor tissue development to predict precisely the efficacy of angiogenic inhibitors. Ultrasound properties based on tumor echogenicity have been demonstrated to be relevant for clinical diagnosis, using echogenicity as a marker of tissue texture (i.e. echo-texture). The HFUS technique has already been used to determine the malignancy of carcinomas. [15] [16] [17] [18] [19] [20] The necrosis detected with ultrasound is seldom used as a prognostic predictor for treatment efficacy. As an example, in 1997 Kenji et al. showed that it could be a relevant tool for determining the efficacy of molecules, such as Lipiocis (CIS Bio-International, Gif-sur-Yvette, France) in the treatment of hepatocellular carcinoma. 21 More recently, the link between the echogenecity and the degree of intra-tumoral necrosis was evaluated in a preclinical study. 22 In this study, we decided to investigate the relative antiangiogenic and antitumor properties of antiangiogenic inhibitors, using contrast-enhanced HFCDUS. We investigated and validated the potential clinical usefulness of contrast-enhanced HFCDUS/HFUS in assessing dynamically the effects of the previously studied angiogenesis inhibitors, Canstatin 14 and K1-5, 23 over a treatment period of 6 weeks, using IHC as the reference standard. Canstatin (Can), a a(NC1) domain fragment of human collagen, and K1-5, a plasminogen-derived protein, are powerful anticancer molecules. For this purpose, we used two recombinant adenoviruses, AdCanHSA and AdK1-5, encoding Canstatin fused with HSA (89 kDa) and the five kringles of plasminogen (65 kDa), respectively. 14, 23 We characterized the natural evolution of vascularization and tumor mass texture with HFCDUS/HFUS in an untreated breast tumor model and correlated this with IHC data, the standard reference for quantifying angiogenesis and necrosis within a tumor.
The xenografted tumor can be easily analyzed by IHC on a single oriented tissue section that visualizes the whole tumor. This method allows the determination of intra-tumor vessels number correlated to a specific tumor volume (mm 3 ). Then, we superimposed ultrasound images with an oriented representative tissue section marked with an anti-endothelial cell antibody to correlate accurately the quantification of the vessels number within the whole tumor volume. 24 Thus, we defined optimal HFCDUS/HFUS parameters necessary to analyze the efficacy of antiangiogenic therapy over 6 weeks, which enabled us to quantify (a) the number of intratumor microvessels and (b) tumor degeneration, for example, necrosis. Importantly, this tool should allow a better understanding of the dynamic events of antiangiogenic therapy and the relationship between endothelial and tumor cells in tumor growth.
Results
Assessment of the efficacy of HFCDUS to visualize texture and microvascularization of tumor masses
To determine the ability of contrast-enhanced HFCDUS to analyze tissue texture and vascularization in the MDA-MB-231-xenografted murine model during the natural evolution of breast cancer, untreated tumors were monitored every week for 6 weeks. The xenografted tumors varied in size from 3 to 9 mm in diameter at week 1 and from 13 to 14 mm at week 6 (data not shown). Sonographic measurements (maximal longitudinal and transverse sections) correlated well with manual measurements and no quantitative difference was found between these two methods. 25, 26 Tumor neovascularization could also be identified in mice with unenhanced color Doppler technique, but this is not sensitive enough to evaluate moderate decreases in tumor vascularity after antiangiogenic therapy. 27 To improve the sensitivity and the specificity of HFCDUS, we injected Levovist, a contrast agent, systematically into untreated xenografted mice. As shown in Figure 1a , the total number of Levovist-enhanced microvessels detected was significantly increased throughout the monitoring period (sevenfold on average as compared to unenhanced tumors, Po10
À4
). In contrast, few intratumor vessels were detected without Levovist. Representative HFCDUS images of breast tumors at week 4 showed detection of a greater number of intra-tumor microvessels as compared to HFUS images (Figure 1b and c).
Ultrasound images allowed us to detect a hypoechogenic subcutaneous oval tumor mass (see green contours around black area in Figure 1b) surrounded by a hyperechogenic area (see green arrows showing white brightened areas in Figure 1b ). 28 Therefore, ultrasound is an effective tool for monitoring tumor size, even in the case of small lesions, and for visualizing the texture of tumor masses. However, contrast agents are clearly required to improve the visualization of intra-tumor vessels through a relatively practical method such as HFCDUS.
Assessment of the reproducible and accurate quantification of intra-tumor microvessels with HFCDUS compared with the number of CD31-stained microvessels Correlation between the histologically and sonographically determined degree of vascularization was not definitively demonstrated. [29] [30] [31] [32] We performed a correlative analysis of IHC and HFCDUS results to determine whether contrast-enhanced ultrasound was as sensitive as IHC (the standard reference) in quantifying tumor microvasculature by IHC using a CD31 immunostaining.
First, the intra-tumor vessels were counted by two independent operators (A and B, Figure 2a ) to determine whether this quantitative HFCDUS method was reproducible. The HFCDUS analysis of recorded visualized Dynamic assessment of angiogenesis and necrosis in tumor mass C Magnon et al sequences consisted of a detailed observation of successive tumor sections during the scan, after injection of contrast agent. Inter-operator reproducibility was found to be strong and significant. The difference between vessels numbers counted by two independent operators varied from 0 to 5, showing a median of 1 (no statistical difference in counting between both operators, P ¼ 0.7) (Figure 2a) .
To determine whether the color Doppler vessel signals were correlated with histological data or not, the number of vessels detected by ultrasound was compared with the number of CD31-stained vessels within a histological section of the same tumor. No correlation was found between IHC and HFCDUS for tumor sizes ranging from 20 to 50 mm 3 . The results indicated that HFCDUS was particularly applicable to tumors with mean volumes exceeding 50 mm 3 . Linear regression analysis, used to determine the vessel detection threshold with HFCDUS as compared to IHC, revealed that sonographic data were well correlated with IHC measurements when the vessel size was approximately 40 mm in diameter (r ¼ 0.915, P ¼ 0.004; Figure 2b ). In contrast, linear regression also demonstrated that HFCDUS was less convincing for vessels measuring 30 mm in diameter (r ¼ 0.697, P ¼ 0.08; data not shown). A representative contrast-enhanced HFCDUS tumor image allowed visualization of vascular zones that were correlated with those detected in the CD31-stained histological section (see green arrows showing corresponding vessels detected with HFCDUS and CD31, and details of the matched areas, numbered 1-4 in Figure 2c ).
Therefore, HFCDUS is a reproducible technique for microvessel detection that was significantly correlated with the conventional indicators of angiogenic activity using anti-CD31 IHC, when tumor volume reaches 50 mm 3 with microvessels of 40 mm diameter.
Evaluation of the ultrasound method in correlating intra-tumor echogenicity with the percentage of tumor necrosis as compared to hematoxylin-eosin-saffranin (HES) staining
Representative images obtained by ultrasound are shown in Figure 3a (lower panel). Simultaneously, the maximal transverse histological section corresponding to ultrasound scan was digitized. As shown in Figure 3a (upper panel), necrotic areas are represented in yellow and viable zones in green. The percentage of necrosis was then determined. In order to evaluate the reproducibility of ultrasound (US) quantification of tumor echogenicity, two independent operators analyzed raw sonographic data with HDILab software. Twenty images of the transverse tumor section were used to determine tumor echogenicity, expressed in decibels (dB). Linear regression showed correlation between both operators in US quantification of intra-tumor echogenicity. To compare the inter-operator reproducibility, results are represented as a median value of 2.0 (values varying from 0.8 to 4.8), assessing differences between operators data ( Figure 3b ).
Histologically quantified necrosis and US-quantified echogenicity are shown in Figure 3c and d, respectively. The percentage of the necrotic area increased throughout the experiment (0% for tumors with a mean volume of 60 mm 3 and 63% for tumors whose volume exceeded 500 mm 3 ) and tumor echogenicity decreased over the same period (18. Figure 3d ). As shown in Figure 3b and c, these data are inversely related. We then expressed echogenicity related to the percentage of necrosis and performed a linear regression, statically validated, where y ¼ À8.1193x+154.36 (r ¼ À0.917; P ¼ 0.01; Figure 3e ), which will be used in a next step of our study to convert intra-tumor echogenicity to the percentage of necrosis.
Evaluation of intra-tumor vascularization with HFCDUS after antiangiogenic treatments
Canstatin and K1-5, two novel angiogenic inhibitors, have the ability to strongly inhibit the development of intra-tumor microvessels. Experiments were previously carried out to verify expression and secretion of CanH and K1-5 in vitro and in vivo. 14, 23 In the present study, microvascularization formation within CanH-or K1-5-treated xenografted tumors was monitored by HFCDUS throughout the treatment period (Figure 4a ). In the control group, 80% (n ¼ 16/20) of tumors were invaded by microvessels (from 1 to 5 vessels per tumor), whereas only 31% (n ¼ 8/26) or 47% (n ¼ 9/19) of tumors developed microvascularization (with 1 or 2 vessels per tumor) after injection of AdCanH or AdK1-5, respectively. For tumors X50 mm 3 , the number of intra-tumor vessels was strongly diminished in the treated groups (0.770.18, P ¼ 0.0005 and 170.27, P ¼ 0.018 for AdCanH and AdK1-5, respectively) as compared with the AdCO1-injected tumors (2.170.34).
Assessment of intra-tumor necrosis with HFUS after antiangiogenic treatments
Similarly, evaluation of intra-tumor necrosis was performed using ultrasound in the same xenografted mice treated with AdCanH or AdK1-5 as described above. For this purpose, intra-tumor echogenicity was quantified precisely with HDILab software. Intra-tumor echogenicity was converted into percentage of necrosis using the standard curve obtained above, where y ¼ À8.1193x+154. 36 .
At the beginning of the treatment, the three groups exhibited similar echogenicity (mean X20dB) related to equivalent tumor volumes (25 mm (Figure 4c ). In the control group, necrosis was not only delayed but was also lower than in treated groups. Indeed, for tumors with volume from 200 to 600 mm 3 , treated tumors had developed over 85% of necrosis whereas necrosis had invaded about 50% of the tumor area in the AdCO1 group (P ¼ 0.003 for AdCanH and P ¼ 0.02 for AdK1-5, Figure 4c ).
Antitumor effects following antiangiogenic treatments dynamically observed with HFCDUS/HFUS
Tumor growth was monitored in AdCO1-, AdCanH-, or AdK1-5-treated groups showing that the two treatments significantly inhibited growth of the MDA-MB-231-derived tumors (Po0.01, data not shown), thereby confirming our previously data.
14,23 Figure 5 shows HFCDUS/HFUS depiction of three parameters (angiogenesis, necrosis, and tumor growth) at different time points (weeks 2, 4, and 6) following treatment with the new antiangiogenic agents (CanH and K1-5 compared to control CO1). The AdCO1 presented an increased intra-tumor vascularization (from 20% at week 2 to 83% at week 4), suggesting that the blood supply might protect the control tumors from necrosis (0% at weeks 2 and 4) and might induce a strong tumor growth (from 35% at week 4 to 100% at week 6). In contrast, the treated groups revealed a decreased vascularization (o40% as compared to the AdCO1 group at week 4 and 6) and an early necrosis (450% at week 4 and 480% at week 6). This combined effect observed on angiogenesis and necrosis might result in a persisting inhibition of tumor growth detectable throughout the 
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C Magnon et al experiment (63 and 75% at week 6 for AdCanH and AdK1-5 groups, respectively). Thus, we showed that HFCDUS and its associated typical standard curve could be a relevant tool for evaluating and classifying new antiangiogenic treatments.
Discussion
The first angiogenesis inhibitor has recently been approved for cancer treatment. However, it remains to optimize the dose of novel angiogenesis inhibitors and to delineate the relationship between their toxicity and their therapeutic response. An in vivo method such as contrast-enhanced high-frequency ultrasonography capable of assessing tumor angiogenesis (with color Doppler, namely HFCDUS) and necrosis (HFUS), as described in this study, would be highly desirable for diagnostic purposes, treatment planning, and follow-up. Breast cancer is suitable for color Doppler ultrasound imaging because of its superficial location, and is a model for the study of in vivo angiogenesis. 14, 23, 33 Clinical ultrasound is already capable of proposing potential clues concerning breast tumor histopathology and can be safely used for monitoring tumor evolution. 34, 35 In this study, the vascularity of xenografted human breast tumors was quantified by HFCDUS and compared to tumor vascularity based on a CD31-staining analysis by IHC. Similarly, tumor necrosis was assessed and precisely quantified through echogenicity data and compared to data obtained with hematoxylin/eosin/ saffranin (HES)-stained slides.
First, we demonstrated that the results obtained with HFCDUS, which were reproducible, accurate, and quantitative, correlate well with intra-tumor vascularity as determined on histological analysis in terms of tumor size (for tumors X50 mm ). According to our results, the sensitivity and the specificity of microvessel detection in living tissue is increased with HFCDUS using microbubble contrast agents that enhance the acoustic signal from blood vessels compared to HFCDUS without contrast agent. 13, 30, 36 Thus, we have demonstrated the threshold of intra-tumor vessel detection of 40 mm in diameter, as proposed by Burns. 37 New interest has developed in contrast-enhanced ultrasound techniques as the unenhanced Doppler ultrasound applied within tumors only depict large vessels (4100 mm) confined to superficial parts of the body. 9, 10 Even if previous studies have reported that unenhanced power-mode Doppler ultrasound system is capable of detecting the velocity of blood flow through tumor vessels as small as 10-20 mm in diameter, this imaging system used high frequencies Dynamic assessment of angiogenesis and necrosis in tumor mass C Magnon et al (50 MHz) and a focused transducer to improve the ultrasound signal resolution and focal characteristics. Nevertheless, this technique is not applicable in clinical settings because high frequency (20-100 MHz) decreases exploration depth, impeding the assessment of deep tumors. 38, 39 Despite the fact that IHC provides a higher resolution than HFCDUS for detecting microvasculature (15 mm 10 and 40 mm in diameter, respectively), we show that HFCDUS presents several major advantages. Previous studies tried to assess tumor angiogenesis on the basis of MVD within the operative specimen as a prognostic marker of survival in many solid tumors. 2, 3, 40 However, in a meta-analysis, which included all clinical trials in breast cancer linking intra-tumor MVD to the probability of survival, Uzzan et al. showed that MVD is a weak prognostic factor despite its significance. 30, [41] [42] [43] More precisely, MVD simply reflects a time-dependent and invasive measurement of a single tumor sample without differentiating ineffective and functional vessels. 3 It is therefore important that a simple and noninvasive technique be developed to measure functional vessel-related angiogenesis with good sensitivity and specificity.
Second, the evaluation of necrosis with HFUS was significantly correlated with the histological quantification in HES-stained specimens. De Luca et al. 44 reported cases of necrotic nodules misdiagnosed as tumors with ultrasound. They emphasized that there was no correlation between US findings and histology. Unlike these authors, our study focused on tumor monitoring over time and not on the diagnosis. Using the MDA-MB-231 breast carcinoma model, we showed that HFUS is a noninvasive, dynamic method but is also sensitive and specific as IHC for accurate quantification of necrosis.
Antiangiogenic therapy is initially active on capillary formation. Subsequent hypoxia induces tissue degeneration and tumor cell eradication. Moreover, some collagen-derived angiogenesis inhibitors also act directly on tumor cells. 5, 6 Many studies have qualitatively investigated vascularity alone using Doppler ultrasonography without correlating the data with IHC assessment of microvasculature. 28, 39, 45 However, more information can be obtained if both the number of vessels and the percentage of necrosis can be quantified precisely. In fact, we chose to precisely quantify alterations of both tumor vascular and tumor cell components following antiangiogenic therapy.
We were able to monitor the antitumor efficacy of two novel antiangiogenic treatments (AdCanHSA or AdK1-5) over 6 weeks with HFCDUS. Angiogenesis and the growth of different tumor models, such as breast tumors, have previously been shown to be suppressed by AdCanHSA or AdK1-5 therapies. 14, 23 Estimating the tumor volume alone is no longer an adequate parameter when evaluating therapy. HFUS would allow the assessment of the tumor echo-texture, an indicator of treatment efficacy by detecting and quantifying residual viable tumor mass. 46 In the present study, we showed the absence of necrosis in control tumors that had reached a mean volume of 200 mm 3 , whereas equivalent-sized, treated tumors exhibited over 50% of necrosis.
Assessing necrosis while monitoring vascularization throughout treatment is very informative in the evaluation of treatment efficacy. Our study showed that MDA-MB-231 carcinoma development is characterized by an early increase in vascularization correlating with an absence of necrosis. This resulting blood supply prevented control tumors from becoming necrotic for tumor volume (50p tumor volume p200 mm 3 ). In contrast, a very different pattern of both vascularization and necrosis was observed in tumors injected with antiangiogenic molecules: potent inhibition of angiogenic network formation was observed from the beginning of treatment resulting in a strong induction of necrosis.
We proposed here a new concept, namely, that the efficacy of angiogenic inhibitors might be measured by quantifying microvessel inhibition in conjunction with the assessment of necrosis. This type of analysis would, therefore, be an efficient tool in clinical examination to establish standard data for each tumor type in response to a specific antiangiogenic therapeutic class. Moreover, combining antiangiogenic molecules with cytotoxic therapies, such as chemotherapy, is an innovative and promising therapeutic strategy. 47, 48 In these cases, HFCDUS and the analysis of tumor volume, vascularization, and necrosis could enable us to identify the additional therapeutic benefit of combined therapy over monotherapy and to optimize the different treatments in Dynamic assessment of angiogenesis and necrosis in tumor mass C Magnon et al such biotherapy (selecting the best molecules and doses) in order to obtain a synergistic effect. In summary, our results indicate that HFCDUS is a reproducible, specific, sensitive, and non-invasive procedure allowing serial measurements of the same tumor mass. This technique seems to be accurate enough to monitor and quantify changes in the number of vessels or tissue degeneration after the administration of antiangiogenic therapeutic agents, and could therefore be useful as a clinical monitoring tool.
Materials and methods

Recombinant adenoviruses
AdCan-HSA and AdK1-5 are both replication-defective recombinant E1E3-deleted adenoviruses directing the expression and secretion of collagen type IV-and plasminogen-derived factors, respectively, under the control of the human cytomegalovirus (CMV) immediate-early promoter. AdCan-HSA expresses the C-terminal non-collagenous (NC1) domain fragment of human a2 chain type IV collagen, and AdK1-5 expresses the N-terminal fragment of human plasminogen containing the full-length kringles 1-5 (AA 1-566). AdCO1 is a control recombinant adenovirus devoid of an expression cassette replacing the E1 genes. These recombinant adenoviruses were obtained, as previously described. 14, 23 Human breast tumor model MDA-MB-231 human breast carcinoma cells were cultured in DMEM with 10% FCS, harvested, washed, and suspended in PBS (20 Â 10 6 cells/ml). 23 In total, 200 ml of the cell suspension were injected s.c. into the flank of 8-week-old athymic mice.
To evaluate spontaneous changes in the tumor vessel distribution and in the echogenicity of breast carcinoma model, untreated MDA-MB 231 tumors (n ¼ 14) were monitored until week 6 post-injection (p.i). Every week, an ultrasound examination was performed. Ultrasoundexamined animals were immediately killed and tumors were removed and marked in order to compare superimposed ultrasonic and digitized histological images.
To evaluate AdCanHSA, AdK1-5, or AdCO1 efficacy, another independent experiment was performed. Animals were randomized to three groups (10 animals per group) when tumor volumes had reached a mean value of 25 mm 3 . All tumors received two intra-tumor injections of 2 Â 10 9 p.f.u. of AdCanHSA, AdK1-5, or AdCO1 in a volume of 50 ml of phosphate-buffered saline (PBS), 48 h apart. In order to assess weekly antiangiogenic and antitumor effects, tumor sizes were monitored (10 mice per group) and tumors were examined by ultrasonography (five mice were randomly chosen at week 1 in each group) until week 6 p.i. The percentage of tumor growth inhibition following antiangiogenic treatment was calculated, as previously described. 23 
Ultrasound protocol
Ultrasound examinations were performed every week over a period of 6 weeks for the treated groups after the beginning of antiangiogenic therapy (day 2 p.i., week 1). Untreated tumors were also analyzed over 6 weeks according to the protocol defined for treated lesions.
These examinations were performed with HFCDUS using an ATL-HDI 5000 sonograph with a 12 MHz linear probe (Model L12-5 38 mm, Philips Ultrasound, Andover, MA, USA). Before the HFCDUS procedure, animals were anesthetized by an intra-peritoneal injection of ketamine (100 mg/kg body weight; Ketalar, Parapharm, France) and xylazine (40 mg/kg body weight, Rompun, Bayer, France).
HFCDUS examinations were then conducted by (1) measuring tumor dimensions and echogenicity on the maximal transverse (width and depth) and longitudinal (length) tumor diameter in sections visualized in B-mode; (2) visualizing intra-tumor vasculature in color Doppler Mode on the transverse scan of the whole tumor.
Intra-tumor vasculature was thus detected before and after a single bolus injection of a 100 ml mixed suspension of D-galactose and palmitic acid (Levovist) at a concentration of 400 mg/ml (Schering, Germany) into the retroorbital sinusoidal vein. Each HFCDUS examination was performed for 2 min following injection of Levovist, according to the instructions of the manufacturer. A total of 114 HFCDUS were performed. In addition, to obtain comparable data for each group and for each day, sonograph settings were recorded and remained unchanged throughout the 6 weeks of the experiments.
Morphologic and echogenic study (HFUS)
To increase image contrast and thus enhance image resolution allowing better visualization of the tumor contours and differences in echo-texture, B-mode investigations were carried out using the SonoCT mode. This specific B-mode computes the final image from eight sonographic sections obtained with different incident beam angles.
Systematically, maximal transverse SonoCT sequences were used for tumor volume estimation, and were digitally transferred to a PC specifically equipped with the HDILab software. This dedicated software allows post-treatment quantification, and particularly that of echogenicity, based on raw data analysis. The mean intensity of 20 images, randomly chosen from each sequence, can be calculated within a region of interest (ROI), namely the whole tumor without interfaces, delineated by the operator. The echogenicity parameter, expressed in decibels (dB), is then defined as the logarithmic value of the mean linear intensity value of 20 sonographic images per sequence. Echogenicity computations were done double-blindly by two different operators (herein after referred to as A and B).
Hemodynamic and functional study (HFCDUS)
Contrast-enhanced color Doppler sequences, recorded on videotapes, were analyzed independently by both operators (A and B) after therapy. The number of intratumor vessels in a whole tumor counted by operators A and B on the transverse scan at given points in time were pooled to obtain mean values.
Histological analysis
Each HFCDUS/HFUS-imaged untreated tumor was sampled every week over a period of 6 weeks to compare ultrasound sensitivity in analyzing the tumor echo-texture and vascularity with the results obtained from the reference standard (IHC). Glyofixx-fixed, Dynamic assessment of angiogenesis and necrosis in tumor mass C Magnon et al paraffin-embedded 4 mm-thick tumor sections were stained with HES, to evaluate tissue viability. The total number of intra-tumor microvessels per tumor was determined after immunolabelling with an anti-CD31 antibody, as previously described. 23, 49 To quantify intra-tumor vessels in untreated tumors, CD31-stained slides were digitized using a microscope and a digital camera, as previously described.
14 For each animal, the whole maximal transverse histological section was analyzed by two observers, including a pathologist, and each vascularized field was digitized at a magnification of Â 25. Each vessel was counted and measured (width Â length) using Matrox Inspector 2.2 software calibration tool. To determine the HFCDUS vessel threshold size detected, the diameter of each vessel was measured and vessels were classified into four categories according to size.
Vessels on the digitized histological slide were correlated topographically with those depicted on the ultrasound sequence.
For histological analysis of necrosis in untreated tumors we (1) determined the position of the histological section corresponding to the transverse sonographic scan; (2) digitized the HES-stained section using a slide scanner (Nikon, Japan) connected to a computer; (3) manually drew, with Adobe Photoshop software, tumor masses (green ROI) and especially, necrotic zones (yellow ROI) in each digitized maximal transverse section. Finally, we quantified the ratio, R ¼ (necrotic area)/ (whole tumor area), using Matrox Inspector 2.2 software. A standard curve was established between the histologically determined percentage of necrosis and ultrasound-quantified echogenicity. Then, the echogenicity of treated tumor tissues was converted into the percentage of necrosis using the standard curve described as the percentage of necrosis ¼ f (echogenicity (dB)).
Statistical analysis
Statistical assessment of the reproducibility of intratumor vessel or echogenicity quantification between the two operators (A and B) was performed using an unpaired Wilcoxon test. Spearman correlation coefficients were obtained. Tumor growth inhibition, microvessel inhibition, and necrosis induced following antiangiogenic therapy were statistically evaluated by the Student's t-test.
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